Tybourne Capital Management HK Ltd. Reduces Holdings in Bicycle Therapeutics plc (NASDAQ:BCYC)

Tybourne Capital Management HK Ltd. lowered its holdings in Bicycle Therapeutics plc (NASDAQ:BCYC) by 7.6% during the 3rd quarter, Holdings Channel reports. The firm owned 1,394,535 shares of the company’s stock after selling 115,178 shares during the period. Bicycle Therapeutics makes up about 8.8% of Tybourne Capital Management HK Ltd.’s investment portfolio, making the stock its 6th largest holding. Tybourne Capital Management HK Ltd.’s holdings in Bicycle Therapeutics were worth $31,558,000 at the end of the most recent quarter.

A number of other institutional investors have also recently bought and sold shares of BCYC. Assetmark Inc. purchased a new stake in shares of Bicycle Therapeutics during the 3rd quarter worth approximately $34,000. GAMMA Investing LLC lifted its stake in Bicycle Therapeutics by 105.1% in the third quarter. GAMMA Investing LLC now owns 2,026 shares of the company’s stock valued at $46,000 after purchasing an additional 1,038 shares during the last quarter. China Universal Asset Management Co. Ltd. grew its holdings in Bicycle Therapeutics by 69.1% during the third quarter. China Universal Asset Management Co. Ltd. now owns 7,138 shares of the company’s stock valued at $162,000 after purchasing an additional 2,918 shares during the period. XTX Topco Ltd purchased a new stake in Bicycle Therapeutics in the second quarter worth $206,000. Finally, Crossmark Global Holdings Inc. bought a new stake in shares of Bicycle Therapeutics in the third quarter valued at $257,000. Institutional investors own 86.15% of the company’s stock.

Insider Activity at Bicycle Therapeutics

In other Bicycle Therapeutics news, CEO Kevin Lee sold 3,212 shares of the business’s stock in a transaction that occurred on Thursday, October 3rd. The shares were sold at an average price of $22.26, for a total value of $71,499.12. Following the completion of the transaction, the chief executive officer now owns 380,864 shares of the company’s stock, valued at $8,478,032.64. The trade was a 0.84 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CAO Travis Alvin Thompson sold 6,256 shares of the firm’s stock in a transaction on Monday, November 11th. The shares were sold at an average price of $25.11, for a total transaction of $157,088.16. Following the sale, the chief accounting officer now owns 19,241 shares in the company, valued at approximately $483,141.51. This trade represents a 24.54 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 10,840 shares of company stock valued at $259,128. Company insiders own 8.50% of the company’s stock.

Analyst Upgrades and Downgrades

Several research firms have recently weighed in on BCYC. Cantor Fitzgerald reiterated an “overweight” rating on shares of Bicycle Therapeutics in a research note on Monday, September 9th. Stephens assumed coverage on shares of Bicycle Therapeutics in a research report on Friday, November 8th. They set an “equal weight” rating and a $25.00 target price for the company. Oppenheimer reiterated an “outperform” rating and issued a $48.00 target price on shares of Bicycle Therapeutics in a research note on Wednesday, August 7th. B. Riley cut shares of Bicycle Therapeutics from a “buy” rating to a “neutral” rating and dropped their price target for the company from $33.00 to $28.00 in a research note on Wednesday, August 7th. Finally, Needham & Company LLC reaffirmed a “buy” rating and issued a $38.00 price objective on shares of Bicycle Therapeutics in a report on Thursday, October 31st. Two equities research analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $40.13.

Bicycle Therapeutics Trading Down 0.2 %

BCYC stock opened at $20.35 on Thursday. The firm has a 50 day moving average of $23.71 and a 200-day moving average of $22.97. The firm has a market capitalization of $967.64 million, a P/E ratio of -6.19 and a beta of 0.89. Bicycle Therapeutics plc has a 12 month low of $13.47 and a 12 month high of $28.67.

Bicycle Therapeutics (NASDAQ:BCYC) last announced its quarterly earnings results on Thursday, October 31st. The company reported ($0.74) EPS for the quarter, beating the consensus estimate of ($0.78) by $0.04. The firm had revenue of $2.68 million during the quarter, compared to the consensus estimate of $6.82 million. Bicycle Therapeutics had a negative net margin of 450.64% and a negative return on equity of 27.35%. The business’s quarterly revenue was down 50.0% compared to the same quarter last year. During the same period last year, the firm earned ($1.26) EPS. Sell-side analysts predict that Bicycle Therapeutics plc will post -3.07 EPS for the current year.

Bicycle Therapeutics Profile

Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. Its product pipeline comprising BT8009, a bicycle toxin conjugate (BTC) which is in phase I/II/III clinical trial for the treatment of high nectin-4 expressing tumors; BT5528, a BTC which is in phase I/II clinical trial for the treatment of Ephrin type A receptor 2 expressing tumor; BT7480, a Bicycle TICA molecule which is in phase I/II targeting Nectin-4 and agonizing CD137; and BT7455, a Bicycle TICA molecule targeting Ephrin type A receptor 2 and CD137 and is in preclinical trial.